ONO PHARMA, Apr-Dec (Cumulative 3Q) Net Income Decreases by 49%, Oct-Dec Net Income Decreases by 59%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Feb 3, 2025 12:00 pm JST Earnings

4528 ONO PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

ONO PHARMACEUTICAL CO., LTD. <4528> [TSE Prime] announced its financial results (based on IFRS) at noon (12:00) on February 3rd. The consolidated net income for the cumulative third quarter of the fiscal year ending March 2025 (April to December) dropped 48.8% from the same period last year to 56.5 billion yen. The progress rate toward the full-year plan of 58 billion yen was 97.6%, also surpassing the five-year average of 85.3%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the January to March period (4Q) is expected to significant drop 91.9% from the same period last year to 1.4 billion yen.

In the most recent three-month period, from October to December (3Q), the consolidated net income significantly dropped to 14.9 billion yen, a 58.5% decrease compared to the same period last year. The operating profit margin sharply declined from 36.3% in the same period last year to 11.1%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	339,020	122,590	124,379	95,656	195.9	86.7	Jan 31, 2023	IFRS
Apr - Dec, 2023	389,903	144,626	147,292	110,544	229.1	90.0	Jan 31, 2024	IFRS
Apr - Dec, 2024	374,562	70,754	72,037	56,592	120.5	88.4	Feb 3, 2025	IFRS
YoY	-3.9%	-51.1%	-51.1%	-48.8%	-47.4%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	243,959	62,899	64,438	53,486	111.4	40	May 9, 2024	IFRS
Oct - Mar, 2024 Guidance	244,661	26,119	26,863	16,359	34.8	40	Oct 31, 2024	IFRS
YoY	+0.3%	-58.5%	-58.3%	-69.4%	-68.7%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	447,187	141,963	143,532	112,723	230.9	70	May 10, 2023	IFRS
Mar, 2024	502,672	159,935	163,734	127,977	266.6	80	May 9, 2024	IFRS
Mar, 2025 Guidance	485,000	82,000	81,500	58,000	123.5	80	Oct 31, 2024	IFRS
YoY	-3.5%	-48.7%	-50.2%	-54.7%	-53.7%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	131,190	47,590	47,996	36,053	74.7	36.3	Jan 31, 2024	IFRS
Jan - Mar, 2024	112,769	15,309	16,442	17,433	36.3	13.6	May 9, 2024	IFRS
Apr - Jun, 2024	117,675	30,690	33,310	24,794	52.8	26.1	Jul 31, 2024	IFRS
Jul - Sep, 2024	122,664	25,191	21,327	16,847	35.9	20.5	Oct 31, 2024	IFRS
Oct - Dec, 2024	134,223	14,873	17,400	14,951	31.8	11.1	Feb 3, 2025	IFRS
YoY	+2.3%	-68.7%	-63.7%	-58.5%	-57.4%